Shares of Vascular Biogenics (NASDAQ:VBLT) decreased 9% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share fell 7.69% year over year to ($0.14), which were in line with the estimate of ($0.14).
Revenue of $158,000 up by 14.49% from the same period last year, which beat the estimate of $150,000.
Guidance
Vascular Biogenics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 13, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/y7tts2sv
Recent Stock Performance
Company's 52-week high was at $1.64
52-week low: $0.90
Price action over last quarter: Up 5.83%
Company Overview
Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
